Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

[1]  M. Weller,et al.  Immunocytokines are a promising immunotherapeutic approach against glioblastoma , 2020, Science Translational Medicine.

[2]  D. Irvine,et al.  Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity , 2020, Nature Cancer.

[3]  A. Mantovani,et al.  Neutrophil diversity and plasticity in tumour progression and therapy , 2020, Nature Reviews Cancer.

[4]  J. Wolchok,et al.  The future of cancer immunotherapy: microenvironment-targeting combinations , 2020, Cell Research.

[5]  J. Hubbell,et al.  Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours , 2020, Nature Biomedical Engineering.

[6]  F. Marincola,et al.  Consensus guidelines for the definition, detection and interpretation of immunogenic cell death , 2020, Journal for ImmunoTherapy of Cancer.

[7]  Y. Arai,et al.  Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade , 2020, Science Translational Medicine.

[8]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[9]  A. Mantovani,et al.  Diversity, Mechanisms, and Significance of Macrophage Plasticity. , 2020, Annual review of pathology.

[10]  P. Lollini,et al.  Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model , 2019, Cancers.

[11]  J. Schlom,et al.  Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy , 2019, Clinical Cancer Research.

[12]  D. Cescon,et al.  Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer , 2019, npj Breast Cancer.

[13]  S. Baylin,et al.  The emerging role of epigenetic therapeutics in immuno-oncology , 2019, Nature Reviews Clinical Oncology.

[14]  A. Nicosia,et al.  Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling , 2019, Scientific Reports.

[15]  C. Peano,et al.  Neutrophils Driving Unconventional T Cells Mediate Resistance against Murine Sarcomas and Selected Human Tumors , 2019, Cell.

[16]  J. Schlom,et al.  Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12 , 2019, Journal of Immunotherapy for Cancer.

[17]  D. Jackson,et al.  Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. , 2019, Cancer cell.

[18]  M. Farrar,et al.  JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors , 2019, Proceedings of the National Academy of Sciences.

[19]  C. Garlanda,et al.  Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. , 2019, Immunity.

[20]  Brian Ruffell,et al.  Macrophages as regulators of tumour immunity and immunotherapy , 2019, Nature Reviews Immunology.

[21]  Ralph Weissleder,et al.  Successful Anti‐PD‐1 Cancer Immunotherapy Requires T Cell‐Dendritic Cell Crosstalk Involving the Cytokines IFN‐&ggr; and IL‐12 , 2018, Immunity.

[22]  J. Schlom,et al.  Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types , 2018, Oncoimmunology.

[23]  S. Workenhe,et al.  HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants. , 2018, Cell reports.

[24]  J. Schlom,et al.  M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine , 2018, Oncoimmunology.

[25]  P. Ordentlich,et al.  Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma , 2017, Clinical Cancer Research.

[26]  J. English,et al.  Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models , 2017, Clinical Cancer Research.

[27]  Weiping Zou,et al.  Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy , 2017, Nature Reviews Immunology.

[28]  J. Schlom,et al.  Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody , 2017, Oncotarget.

[29]  M. Rudek,et al.  Entinostat: a promising treatment option for patients with advanced breast cancer. , 2017, Future oncology.

[30]  Robert R Yauch,et al.  Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice , 2017, Nature Communications.

[31]  Burkhard Becher,et al.  GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation. , 2016, Immunity.

[32]  J. Trepel,et al.  The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat , 2016, Oncoimmunology.

[33]  J. Schlom,et al.  IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas , 2016, Oncotarget.

[34]  S. Ferrone,et al.  Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells , 2016, Oncotarget.

[35]  P. Munster,et al.  Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. , 2015, Epigenomics.

[36]  M. Kiupel,et al.  Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma , 2015, PloS one.

[37]  B. Becher,et al.  New insights into IL-12-mediated tumor suppression , 2014, Cell Death and Differentiation.

[38]  G. Adema,et al.  HDAC inhibitors and immunotherapy; a double edged sword? , 2014, Oncotarget.

[39]  K. Kinzler,et al.  Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells , 2014, Journal of Immunotherapy for Cancer.

[40]  J. Schlom,et al.  The immunocytokine NHS-IL12 as a potential cancer therapeutic , 2014, Oncotarget.

[41]  G. Natoli,et al.  Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages , 2012, Proceedings of the National Academy of Sciences.

[42]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[43]  L. Ellis,et al.  Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models , 2012, PloS one.

[44]  F. Marincola,et al.  IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. , 2011, The Journal of clinical investigation.

[45]  J. Schlom,et al.  Intratumoral Immunotherapy of Established Solid Tumors With Chitosan/IL-12 , 2010, Journal of immunotherapy.

[46]  L. Moretta,et al.  Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. , 2008, Cancer letters.

[47]  M. Del Vecchio,et al.  Interleukin-12: Biological Properties and Clinical Application , 2007, Clinical Cancer Research.

[48]  S. Steinberg,et al.  Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. , 2006, Blood.

[49]  E. Sausville,et al.  Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  I. Flinn,et al.  Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease , 2004, Clinical Cancer Research.

[51]  J. Prieto,et al.  Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  P. Lollini,et al.  TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma , 1983, Clinical & Experimental Metastasis.

[53]  L. Khawli,et al.  Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors. , 2001, Hybridoma and hybridomics.

[54]  M. Atkins,et al.  Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  G. Wood,et al.  Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. , 1999, Blood.

[56]  U. Grohmann,et al.  IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. , 1998, Immunity.

[57]  S. Gillies,et al.  Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. , 1998, Journal of immunology.

[58]  G. Trinchieri,et al.  Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. , 1994, Cellular immunology.

[59]  G. Trinchieri,et al.  Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells , 1993, The Journal of experimental medicine.

[60]  P. Hand,et al.  Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. , 1991, Cancer research.